Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.94 USD
0.00 (0.30%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $0.93 -0.01 (-1.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Lineage Cell Therapeutics, Inc. [LCTX]
Reports for Purchase
Showing records 1 - 20 ( 100 total )
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Waiting on Roche Data as Major Driver; OPC1 Study Expected in Near-Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Roche Signs New Services Agreement On Top of Existing Global Partnership
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Seeing Continues to Be Believing; Roche Presents Impressive 24-Month OpRegen Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Spends $25M in 2023, and $35M in Cash Plus $14M - Funded through 3Q2025
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Updated OpRegen Durability Impresses Solidifying Roche''s Global Partner Role
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: FDA Clears IND (amendment) for OPC1 Cell Transplant for Spinal Cord Injury
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory Green Light For OPC1 and DOSED Study Represents Important Day For LCTX
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OPC1''s IND Amendment Submitted For SCI; Awaiting FDA Decision to Kickstart DOSED Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reports the Quarter - Stock Makes New Lows, Lowering Price Target from $6 to $2
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; OpRegen Focused on Differentiation; Pipeline Progressing as Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Global Partner Genentech Reveals Rapid and Sustained Benefits of OpRegen in GA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: OPREGEN P1/2A Additional Results to be Featured at the 23rd EURETINA Congress
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy Pipeline Expands as Development Activities Commence For Partnered Neurology Candidates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Pipeline Buzzing and OpRegen Global Partner Pushes Forward; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Lineage Cell Cancer Research UK: Topline Phase 1 Data of VAC2 in Advanced NSCLC- Early Data Appears Promising
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VAC2 Phase 1 Data Highlight the Potential of Using a Cancer Vaccine in NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We See Important Convergence of Strategy Coming for Spinal Cord Injury; Thoughts Post-First Annual SCI Investor Conf
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Perfect Timing to Push for OPC1 and VAC2 While OpRegen Phase 1/2a Progresses as Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: OpRegen P1/2a - Proof of Concept Presented
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J